In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Ferring Beefing Up Reproductive Health Biz in Japan, Sets Up Specialized Sales Team
January 31, 2018
- Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring
January 31, 2018
- Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
January 31, 2018
- US FDA Fast-Tracks Takeda’s Zika Vaccine Candidate
January 31, 2018
- Otsuka Bags US$10 Million Grant from Gates Foundation for Development of Anti-TB Drug
January 31, 2018
- Hiroshima Couple Served with Arrest Warrant over Counterfeit Harvoni
January 30, 2018
- Novartis Seeks Ankylosing Spondylitis Nod for Cosentyx in Japan
January 30, 2018
- New GSK Japan President to Take Office on Feb. 1
January 30, 2018
- Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster
January 30, 2018
- New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head
January 29, 2018
- Takeda Fails in Key Actos Trial for Alzheimer’s
January 26, 2018
- Contract Sales Reps in Japan Log Largest Dip in 2017: Industry Group
January 25, 2018
- Takeda Ramps Up Inisync Pitch in November: Anterio Ranking
January 25, 2018
- Mitobridge Acquisition Completed: Astellas
January 25, 2018
- Swiss Regulator Accepts Edaravone for ALS: Mitsubishi Tanabe
January 24, 2018
- Miraca Inks Exclusive Service Accord with Myriad for Lynparza CDx
January 24, 2018
- Opdivo Earns Gastric Cancer Nod in Taiwan
January 24, 2018
- Adcetris Adds CTCL Indication in Europe
January 24, 2018
- Gilteritinib Grabs EU Orphan Status for AML: Astellas
January 24, 2018
- Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End
January 24, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…